Hormone replacement therapy (HRT), breast cancer and tumor pathology

Maturitas

Volumn 65, Issue 3, 2010, Pages 183-189

  Dietel, Manfred ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Breast cancer; Estrogen; Hormone replacement therapy; Pathology; Review; Tumor doubling time

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE; STEROID HORMONE;

BREAST CANCER; BREAST EPITHELIUM; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; DRUG EFFECT; HEALTH PROMOTION; HORMONE SUBSTITUTION; HUMAN; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR GROWTH; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS;

EID: 76349096691     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.11.005     Document Type: Review

References (85)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288 (2002) 321-333
2. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
3. Vickers M.R., Martin J., and Meade T.W. WISDOM study team. The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Women's Health 7 (2007) 2
4. Turgeon J.L., McDonnell D.P., Martin K.A., and Wise P.M. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304 5675 (2004) 1269-1273
5. American Institute for Cancer Research/World Cancer Research Fund. Food, nutrition and the prevention of cancer: a global perspective. Breast (2002), American Institute of Cancer Research, Washington, DC, USA p. 252-287, 20009, ISBN: 1 899533 05 2
6. Skouby S.O., and Jespersen J. Progestins in HRT: sufferance or desire?. Maturitas 62 (2009) 371-375
7. Brekelmans C.T. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15 (2003) 63-68
8. Colditz G.A., Hankinson S.E., Hunter D.J., et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332 (1995) 1589-1593
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 54 (1996) 1S-106S
10. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350 (1997) 1047-1059
11. Endogenous Hormones, Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (2002) 606-616
12. Hankinson S., and Hunter D. Breast cancer. In: Adami H.O., Hunter D., and Trichopoulos D. (Eds). Textbook of cancer epidemiology (2002), Oxford University Press, New York 301-339
13. La Vecchia C., and Franceschi S. Hormone replacement therapy and cancer: an update. Eur J Cancer Prev 12 (2003) 3-4
14. Magnusson C., Baron J.A., Correia N., Bergström R., Adami H.O., and Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 (1999) 339-344
15. Olsson H.L., Ingvar C., and Bladström A. Hormone replacement therapy containing progestins and given continuously increase breast carcinoma risk in Sweden. Cancer 97 (2003) 1387-1392
16. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 485-491
17. Porch J.V., Lee I.-M., Cook N.R., Rexrode K.M., and Buring J.E. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 13 (2002) 847-854
18. Ewertz M., Mellemkjaer L., Poulsen A.H., et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92 (2005) 1293-1297
19. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289 (2003) 3243-3253
20. Speroff L. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Menopause 15 (2008) 393-400 [Review]
21. Dietel M., and Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448 (2006) 744-755 [Review]
22. Dietel M. Predictive medicine: incipient reality or fata morgana?. J Pathol 12 (2007) 353-355
23. Adami H.-O., Signorello L.B., and Trichopoulos D. Towards an understanding of breast cancer etiology. In: Adami H.-O., and Trichopoulos D. (Eds). Progress and enigmas in cancer epidemiology vol. 8 (1998), Seminars in Cancer Biology 255-262
24. Hofseth L.J., Raafat A.M., Osuch J.R., Pathak D.R., Slomski C.A., and Haslam S.Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84 (1999) 4559-4565
25. Li C.I., Weiss N.S., Stanford J.L., and Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88 (2000) 2570-2577
26. Li C.I., Malone K.E., Porter P.L., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289 (2003) 3304-3306
27. Wiseman R.A. Breast cancer hypothesis: a single cause for the majority of cases. J Epidemiol Community Health 54 (2000) 851-858
28. Dietel M., Lewis M.A., and Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20 (2005) 2052-2060
29. Kulendran M., Salhab M., and Mokbel K. Oestrogen-synthesising enzymes and breast cancer. Anticancer Res 29 (2009) 1095-1109 [Review]
30. Slanger T.E., Chang-Claude J.C., Obi N., et al. Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 18 (2009) 1188-1196
31. Kumar A.S., Cureton E., Shim V., et al. Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol 14 (2007) 695-703
32. Tjønneland A., Christensen J., Thomsen B.L., et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 100 (2004) 2328-2337
33. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
34. Friberg S., and Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65 (1997) 284-297
35. Spratt J.S., Meyer J.S., and Spratt J.A. Rates of growth of human solid neoplasms. Part I. J Surg Oncol 60 (1995) 137-146
36. Shackney S.E., McCormack G.W., and Cuchural Jr. G.J. Related articles, growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med 89 (1978) 107-121
37. Spratt J.S., Kaltenbach M.L., and Spratt J.A. Cytokinetic definition of acute and chronic breast cancer. Cancer Res 37 (1977) 226-230
38. Spratt J.S., and Spratt J.A. What is breast cancer doing before we can detect it?. J Surg Oncol 30 (1985) 156-160
39. Gershon-Cohen J., Berger S.M., and Klickstein H.S. Roentgenography of breast cancer. Moderating concept of biologic predeterminism. Cancer 16 (1963) 961-964
40. Gompertz B. On the nature of the function expressive of the law of human mortality and on a new mode of determining the value of life contingencies. Philos Trans Roy Soc Lond (Biol) 115 (1825) 513-583
41. Sausville E.A., and Longo D.L. Principle of cancer treatment: surgery, chemotherapy and biological therapy. In: Harrisson (Ed). Principle of internal medicine. 16th ed. (2005), McGraw-Hill, NY p. 464
42. Haskell C.M. Thorax and unknown primary-breast cancer in cancer treatment. 2nd ed. (1985), WB Saunders Company p. 138
43. Kusama S., Spratt Jr. J.S., Donegan W.L., Watson F.R., and Cunningham C. The cross rates of growth of human mammary carcinoma. Cancer 30 (1972) 594-599
44. Peer P.G., Holland R., Hendriks J.H., Mravunac M., and Verbeek A.L. Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness. J Natl Cancer Inst 86 (1994) 436-441
45. Kuroishi T., Tominaga S., Morimoto T., et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Jpn J Cancer Res 81 (1990) 454-462 [Review]
46. Fournier D.v., Weber E., Hoeffken W., Bauer M., Kubli F., and Barth V. Growth rate of 147 mammary carcinomas. Cancer 45 (1980) 2198-2207
47. Arnerlöv C., Emdin S.O., Lundgren B., et al. Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population. Cancer 70 (1992) 1928-1934
48. Hankinson S.E., Willet W.C., Colditz G.A., et al. Endogeneous and exogeneous hormone factors. In: Harris J.R., Lippman M.E., Morrow M., and Hellman S. (Eds). Disease of the breast (1996), Lippincott-Raven Publishers, Philadelphia, PA 185-200
49. Sellers T.A., Mink P.J., Cerhan J.R., et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 127 (1997) 973-980
50. Fletcher A.S., Erbas B., Kavanagh A.M., Hart S., Rodger A., and Gertig D.M. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. Breast 14 (2005) 192-200
51. Gapstur S.M., Morrow M., and Sellers T.A. Hormone replacement therapy and risk of breast cancer with a favorable histology. JAMA 281 (1999) 2091-2097
52. Hall P., Ploner A., Bjöhle J., et al. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med 4 (2006) 16
53. Pappo I., Meirshon I., Karni T., et al. The characteristics of malignant breast tumors in hormone replacement therapy users versus nonusers. Ann Surg Oncol 11 (2004) 52-58
54. Sacchini V., Zurrida S., Andreoni G., et al. Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9 (2002) 266-271
55. Erbas B., Amos A., Fletcher A., Kavanagh A.M., and Gertig D.M. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?. Cancer Epidemiol Biomarkers Prev 13 (2004) 1569-1573
56. Pirke K.M., and Doerr P. Age-related changes in free plasma testosterone, dihydrotestosterone, and oestradiol. Acta Endocrinol 80 (1975) 171-178
57. Neuhouser M.L., Kristal A.R., and Penson D.F. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Urology 64 (2004) 201-211
58. WHO Classification of tumors-Pathology and genetics of tumours of the urinary system and male genital organs. Eds. Eble JE, Sauter G, Epstein JI, Sesterhenn IA, IARC Press, Lyon 2004, p. 164.
59. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12 (1988) 897-906
60. Erbersdobler A.H., Augustin T., and Schlomm R.-P. Henke prostate cancers in the transition zone. Part 1. Pathological aspects. BJU Int 94 (2004) 1221-1225
61. Low T.H., Clark J., Gao K., Eris J., Shannon K., and O'Brien C. Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ J Surg 79 (2009) 378-382
62. Anderson G.L., Limacher M., Assaf A.R., et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
63. Seeger H., and Mueck A.O. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 109 (2008) 11-15
64. Pike M.C., Wu A.H., Spicer D.V., Lee S., and Pearce C.L. Estrogens, progestins, and risk of breast cancer. Ernst Schering Found Symp Proc 1 (2007) 127-150 [Review]
65. Ferguson D.J., and Anderson T.J. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer 44 (1981) 177-181
66. Lee S.A., Ross R.K., and Pike M.C. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 92 (2005) 2049-2058
67. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
68. Lyytinen H., Pukkala E., and Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 113 (2009) 65-73
69. Birrell S.N., Butler L.M., Harris J.M., Buchanan G., and Tilley W.D. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J 21 (2007) 2285-2293
70. Eigeliene N., Härkönen P., and Erkkola R. Effects of estradiol and medroxyprogesterone acetate on expression of the cell cycle proteins cyclin D1, p21 and p27 in cultured human breast tissues. Cell Cycle 7 (2008) 71-80
71. Eigeliene N., Härkönen P., and Erkkola R. Effects of estradiol and medroxyprogesterone acetate on morphology, proliferation and apoptosis of human breast tissue in organ cultures. BMC Cancer 6 (2006) 246
72. Hackenberg R., Turgetto I., Filmer A., and Schulz K.D. Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells. J Steroid Biochem Mol Biol 46 5 (1993) 597-603
73. Birrell S.N., Hall R.E., and Tilley W.D. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 3 (1998) 95-103 [Review]
74. Hall R.E., Birrell S.N., Tilley W.D., and Sutherland R.L. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with a high level of androgen receptor expression. Eur J Cancer 30A (1994) 484-490
75. Recchione C., Venturelli E., Manzari A., Cavalteri A., Martinetti A., and Secreto G. Testosterone, dihydrotestosterone and estradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 52 (1995) 541-546
76. Søreide J.A., Lea O.A., Varhaug J.E., Skarstein A., and Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur J Surg Oncol 18 (1992) 112-118
77. Schippinger W., Regitnig P., Dandachi N., et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449 (2006) 24-30
78. Buchanan G., Birrell S.N., Peters A.A., et al. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res 65 (2005) 8487-8496
79. Parazzini F., Colli E., Scatigna M., and Tozzi L. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology 50 (1993) 483-489
80. Taoufik R., Ouatas T., Halverson D., and Steeg P.S. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 9 (2003) 3763-3772
81. In: Stewart B.W., and Kleihues P. (Eds). WHO World Cancer Report (2003), IARC Press, Lyon
82. Holmes M.D., Chen W.Y., Feskanich D., Kroenke C.H., and Colditz G.A. Physical activity and survival after breast cancer diagnosis. JAMA 293 May (20) (2005) 2479-2486
83. Armstrong K., Eisen A., and Weber B. Assessing the risk of breast cancer. N Engl J Med 342 (2000) 564-571
84. Harris J.R., Lippman M.E., Veronesi U., and Willett W. Breast cancer. N Engl J Med 327 1 (1992) 319-328
85. Boyd N.F., Rommens J.M., Vogt K., et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6 (2005) 798-808